<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-29 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-29</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-29</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-0f4d3a7384965856049f49d5ede5d6f07d628d13</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/0f4d3a7384965856049f49d5ede5d6f07d628d13" target="_blank">CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES</a></p>
                <p><strong>Paper TL;DR:</strong> The description of the cancer immunotherapy mechanisms in the context of current therapy decisions for the treatment of cancer and the including criteria for those patients with cancer who could be appropriate candidates for immunotherapy are described.</p>
                <p><strong>Paper Abstract:</strong> The aim of this publication includes the try to act as intermediary to the readers, which should be able to understand: · The description of the cancer immunotherapy mechanisms in the context of current therapy decisions for the treatment of cancer · The including criteria for those patients with cancer who could be appropriate candidates for immunotherapy · And to optimize patient outcomes by using best practices to manage the adverse events associated with immunotherapy treatment More than 15 promising immunotherapy approaches being tested in clinical trials with appropriate patients and colleagues for enrollment and peer-to-peer education purposes, respectively.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e29.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e29.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pembrolizumab Phase I (Hamid/Robert expansion)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pembrolizumab (lambrolizumab/MK-3475) phase I dose-escalation and ipilimumab-refractory expansion cohort in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase I dose-escalation and expansion cohorts of the anti-PD-1 antibody pembrolizumab in patients with metastatic or unresectable melanoma, including ipilimumab-refractory patients; treatment given at multiple dose levels with treatment continued until progression or unacceptable toxicity and with efficacy assessed by RECIST and immune-related response criteria.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Cancer immunology and immunotherapy – understanding and adaptation the current evidence to optimize patient therapy outcomes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>Hamid et al. phase I dose-escalation and Robert et al. ipilimumab-refractory expansion cohort (reported within this review)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>metastatic/advanced (including ipilimumab-refractory)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Treatment continued until disease progression, unacceptable toxicity, or withdrawal of consent; patients with progression at first evaluation could continue until confirmatory imaging. Dosing schedules evaluated included 10 mg/kg q2w, and 2 mg/kg q3w vs 10 mg/kg q3w in randomized expansion.</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Objective response rate (ORR) by RECIST and immune-related response criteria; tumor burden reductions; categories implicit: CR, PR, SD, PD (RECIST/immune-related criteria used)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Across initial cohorts reported in this review: ORR 37% by immune-related response criteria and 38% confirmed by RECIST across tested doses in the dose-escalation cohort; in the ipilimumab-refractory randomized expansion cohort ORR = 26% at both 2 mg/kg q3w and 10 mg/kg q3w. Median PFS (central review) reported as 22 weeks for 2 mg/kg q3w and 14 weeks for 10 mg/kg q3w; median PFS by immune-related criteria was 31 weeks (2 mg/kg) and 35 weeks (10 mg/kg). One-year overall survival was 58% (2 mg/kg) and 63% (10 mg/kg). No explicit comparison of fixed-duration vs until-progression strategies was reported; comparisons reported are dose cohorts rather than duration strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>The review reports overall response rates and that ~70% of patients had reductions in tumor burden; responses occurred as late as 36 weeks. The paper does not provide detailed survival or relapse rates stratified by CR vs PR vs SD for pembrolizumab within the discussed trials.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Not reported in detail for pembrolizumab cohorts in this review; durability of responses described qualitatively (responses durable) but precise relapse rates or retreatment outcomes after stopping are not given.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade 3/4 treatment-related adverse events reported in phase I cohorts ~12–13% in pooled pembrolizumab data cited in the review; toxicities included rare pneumonitis (< grade 3), rash, diarrhea, fatigue, autoimmune hepatitis. The review does not provide toxicity stratified by duration of exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES', 'publication_date_yy_mm': '2015-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e29.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e29.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Nivolumab Phase I (melanoma)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Nivolumab (BMS-936558/ONO-4538) phase I melanoma cohorts</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Early-phase data for the anti-PD-1 antibody nivolumab in metastatic melanoma showing rapid and durable objective responses with a substantial fraction of responses early and long median duration of response; treatment generally continued until progression/toxicity in these trials.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Cancer immunology and immunotherapy – understanding and adaptation the current evidence to optimize patient therapy outcomes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>Nivolumab phase I melanoma cohorts (reported as pooled/phase I data in the review; Sznol/Topalian et al. reports cited)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>metastatic/advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>In the referenced phase I trials, nivolumab was administered repeatedly until disease progression or unacceptable toxicity (standard phase I/expansion approach); the review notes early responses and some patients stopping while remaining in response but does not define a fixed duration protocol.</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>ORR (reported as 31% in melanoma phase I), time-to-response (45% of responders by 8 weeks), and duration of response (median duration of response reported). RECIST and immune-related assessments referenced.</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Reported phase I metrics in melanoma within this review: ORR approximately 31%; 45% of responders achieved response within 8 weeks; median duration of response ~2 years. The review notes that some responses persisted after discontinuation. No formal efficacy comparison by different planned treatment durations was reported.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>The review does not provide stratified survival metrics (OS/PFS) by CR vs PR vs SD for nivolumab in melanoma; it reports median duration of response (~2 years) as a durability metric for responders.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Review notes that some nivolumab responses persisted after discontinuation (qualitative statement); no numerical relapse rates or retreatment data provided.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade 3+ toxicities reported as relatively minimal compared with ipilimumab in phase I data; review notes pneumonitis caused 2 deaths in early trials. No toxicity rates explicitly tied to longer vs shorter treatment durations were reported.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES', 'publication_date_yy_mm': '2015-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e29.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e29.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Nivo + Ipi combination (Wolchok)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Combination nivolumab plus ipilimumab in advanced melanoma (concurrent vs sequential dosing cohorts)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase I dose-escalation and cohort study combining anti-PD-1 (nivolumab) with anti-CTLA-4 (ipilimumab) in metastatic melanoma showing more rapid and higher response rates than monotherapy, but substantially increased grade 3/4 toxicity; different concurrent and sequential schedules evaluated.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Cancer immunology and immunotherapy – understanding and adaptation the current evidence to optimize patient therapy outcomes</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>Wolchok et al. nivolumab plus ipilimumab phase I trial (as described in this review)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (combined with ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>metastatic/advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Multiple cohorts: concurrent dual-antibody administration vs sequential cohorts with varying dose levels; specific schedules included nivolumab 1 mg/kg + ipilimumab 3 mg/kg in some cohorts and the reverse ratio in others. Treatment duration per protocol varied by cohort; review does not state a single fixed duration rule beyond cohort-specific dosing and continuation per protocol until progression/toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Objective response rate (ORR), time to response (noting ~75% of responses occurred before 12 weeks), immune-related and RECIST assessments; overall survival reported for cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>The review reports higher ORRs with combination therapy: a reported confirmed ORR across cohorts ranged (text reports 40% confirmed ORR in one summary and explicitly 53% ORR in the concurrent combination group). Responses were more rapid than monotherapy (≈75% before 12 weeks). Updated survival data cited: 2-year OS rates of 88% in a sequential cohort (nivolumab 1 mg/kg and ipilimumab 3 mg/kg sequentially, n=17) and 79% in the concurrent dual-antibody therapy cohort (n=53). These efficacy metrics are cohort-based rather than comparisons of different planned treatment durations.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>The review does not provide CR/PR/SD-stratified survival rates beyond cohort-level ORR and 2-year OS figures; no detailed relapse rates by response category are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Not reported in detail; the review emphasizes rapidity and durability of responses in many patients but does not enumerate outcomes after planned or unplanned stopping.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>High grade 3/4 treatment-related adverse event rates reported: approximately 53% grade 3/4 in the melanoma combination trial referenced. The review also notes that toxicity is influenced by the relative dosing ratio (ipilimumab dose driving toxicity) in analogous RCC data.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES', 'publication_date_yy_mm': '2015-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma <em>(Rating: 2)</em></li>
                <li>Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial <em>(Rating: 2)</em></li>
                <li>Nivolumab plus ipilimumab in advanced melanoma <em>(Rating: 2)</em></li>
                <li>Survival, durable remission, and long-term safety in patients with advanced melanoma receiving nivolumab <em>(Rating: 1)</em></li>
                <li>Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>